ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 1
Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.
- Briefly explore the current landscape of first-line treatment for limited-stage small cell lung cancer:
- What clinical factors influence or impact the initial diagnostic workup and management of patients with LS-SCLC?
- To what degree is a multidisciplinary team approach adopted when developing a treatment plan for patients with SCLC?
- With respect to limited-stage disease, which patients are most likely to benefit from surgery and does lobectomy remain the preferred procedure for stageI-IIA (T1-2,N0,M0) disease?
- To what degree does pathologic mediastinal lymph node stage influence your treatment path?
- Under what circumstances would surgery versus RT be a preferred approach for a patient with stage I-IIA SCLC?
Related Content:
